Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-08-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
董事会秘书工作细则（2022年8月）
Governance Information Classification · 95% confidence The document is titled '深圳华大基因股份有限公司 董事会秘书工作细则' which translates to 'Shenzhen BGI Genomics Co., Ltd. Board Secretary Work Rules'. It details the roles, qualifications, appointment procedures, responsibilities, legal liabilities, and work procedures of the company's board secretary. The content is focused on governance practices and internal rules related to the board secretary function. There is no financial data, no earnings or annual report content, no voting results, no capital or financing updates, no legal proceedings, no merger or acquisition information, and no regulatory filings or announcements. The document is a governance-related internal policy document. Therefore, it fits best under the category 'Governance Information (CGR)', which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is sufficient and the content is substantive, not a mere announcement or certification. Confidence is high due to clear alignment with governance information.
2022-08-12 Chinese
对外担保管理制度（2022年8月）
Governance Information Classification · 95% confidence The document is titled '深圳华大基因股份有限公司 对外担保管理制度' which translates to 'Shenzhen BGI Co., Ltd. External Guarantee Management System'. It is a detailed internal policy document outlining the rules, procedures, responsibilities, and disclosure requirements related to the company's external guarantees. It references relevant laws, company bylaws, and regulatory requirements. The document is not a financial report, earnings release, or announcement but rather a governance and compliance manual related to external guarantees. It does not contain financial statements or audit results, nor is it a notice or announcement of a report. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-08-12 Chinese
独立董事制度（2022年8月）
Governance Information Classification · 100% confidence The document is titled '独立董事制度' which translates to 'Independent Director System' and contains detailed provisions about the qualifications, nomination, election, duties, and protections of independent directors at Shenzhen BGI Genomics Co., Ltd. It references relevant laws, regulations, and governance codes, and outlines governance practices related to independent directors. There is no financial data, earnings information, or report publication announcement. The content is focused on governance structure and internal rules regarding independent directors, which fits the definition of Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification. Therefore, the document is best classified as Governance Information (CGR).
2022-08-12 Chinese
防止控股股东及其关联方资金占用专项制度（2022年8月）
Governance Information Classification · 95% confidence The document is titled as a special system to prevent controlling shareholders and their related parties from occupying company funds. It contains detailed internal governance rules, principles, responsibilities, and penalties related to controlling shareholders' behavior and fund management. There is no indication of financial statements, audit results, or regulatory filings. The content is focused on governance practices and internal control policies related to shareholder conduct and fund usage. It is not a report of financial results, audit, or regulatory announcement, but rather a governance-related policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4526 characters, which is sufficient for a substantive policy document rather than a brief announcement.
2022-08-12 Chinese
独立董事关于第三届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several related-party transactions and investment projects discussed at the company's third board of directors' ninth meeting. It references compliance with stock exchange listing rules and company governance documents, and provides independent opinions on specific board meeting agenda items. The content focuses on board meeting matters and independent directors' opinions rather than financial results, audit reports, or regulatory filings. It is not a full annual or interim report, nor an earnings release or capital update. The document is related to board/management information, specifically independent directors' opinions on board meeting matters, which fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2022-08-12 Chinese
独立董事关于第三届董事会第九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is titled as an opinion from independent directors regarding matters to be discussed at the company's third board of directors' ninth meeting. It contains pre-approval opinions on related party transactions and investment proposals to be submitted to the board meeting. The content focuses on governance and board-level decision-making rather than financial results, audit, or shareholder voting outcomes. It is not a full report, earnings release, or regulatory filing but rather a board/management information document related to board meeting agenda items and approvals. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and does not contain financial statements or voting results, so it is not AGM materials or voting results announcements.
2022-08-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.